STOCK TITAN

[Form 4] PAVmed Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

PAVmed Inc. (PAVM) reported a Form 4 showing that Michael A. Gordon, the company's General Counsel, was granted 150,000 shares of common stock on 09/30/2025. The award is restricted stock issued under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and carries a single vesting date of May 20, 2028. The shares have a reported acquisition price of $0 and are subject to forfeiture if the required service period is not completed. Following the grant, the reporting person beneficially owns 150,000 shares directly. The form is signed by the reporting person on 10/02/2025.

PAVmed Inc. (PAVM) ha riportato un Form 4 che mostra che Michael A. Gordon, l'General Counsel dell'azienda, è stato assegnato 150.000 azioni ordinarie il 30/09/2025. Il premio è azioni soggette a restrizioni emesse ai sensi del Sesto Amended and Restated 2014 Long-Term Incentive Equity Plan dell'emittente e presenta una sola data di vesting del 20 maggio 2028. Le azioni hanno un prezzo di acquisizione riportato di $0 e sono soggette a perdita se non viene completato il periodo di servizio richiesto. Dopo l'assegnazione, la persona che riporta detiene beneficiamente 150.000 azioni direttamente. Il modulo è firmato dalla persona che riporta il 02/10/2025.

PAVmed Inc. (PAVM) reportó un Form 4 que muestra que Michael A. Gordon, el Asesor General de la empresa, recibió 150,000 acciones comunes el 30/09/2025. La adjudicación es de acciones restringidas emitidas conforme al Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan del emisor y tiene una única fecha de vesting el 20 de mayo de 2028. Las acciones tienen un precio de adquisición reportado de $0 y están sujetas a pérdidas si no se completa el periodo de servicio requerido. Después de la adjudicación, la persona que reporta posee beneficialmente 150,000 acciones directamente. El formulario está firmado por la persona que reporta el 02/10/2025.

PAVmed Inc. (PAVM)은 Michael A. Gordon이 회사의 General Counsel로서 150,000 주의 일반 주식을 2025년 9월 30일에 부여받았다고 Form 4를 통해 보고했습니다. 이 수여는 발행인의 제6차 수정 및 재정된 2014년 장기 인센티브 지분 계획에 따라 발행된 제한 주식이며, 단일 가취일은 2028년 5월 20일입니다. 주식의 취득가액은 $0이며 필요한 서비스 기간을 완료하지 못하면 몰수될 수 있습니다. 수여 이후 보고자는 직접적으로 150,000주를 수익적으로 소유합니다. 이 양식은 보고자가 2025년 10월 2일에 서명했습니다.

PAVmed Inc. (PAVM) a déclaré un formulaire 4 montrant que Michael A. Gordon, le conseiller juridique général de la société, a reçu 150 000 actions ordinaires le 30/09/2025. La récompense est des actions restreintes émises en vertu du Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan de l’émetteur et comporte une seule date d’acquisition, le 20 mai 2028. Les actions ont un prix d’acquisition déclaré de $0 et sont susceptibles d’être annulées si la période de service requise n’est pas accomplie. Après l’attribution, la personne déclarant détient avantageusement 150 000 actions directement. Le formulaire est signé par la personne déclarant le 02/10/2025.

PAVmed Inc. (PAVM) meldete ein Form 4, das zeigt, dass Michael A. Gordon, der General Counsel des Unternehmens, am 30.09.2025 150.000 Stammaktien erhalten hat. Die Zuwendung sind eingeschränkte Aktien, ausgegeben gemäß dem Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan des Emittenten, und sie hat ein einziges Vesting-Datum am 20. Mai 2028. Die Aktien haben einen gemeldeten Anschaffungspreis von $0 und unterliegen dem Verlust, falls der erforderliche Dienstzeitraum nicht abgeschlossen wird. Nach der Zuwendung besitzt die meldende Person direkt 150.000 Aktien beneficioell. Das Formular ist von der meldenden Person am 02.10.2025 unterschrieben.

PAVmed Inc. (PAVM) أصدرت نموذج 4 يُظهر أن مايكل أ. غاردون، المستشار العام للشركة، مُنح 150,000 سهماً من الأسهم العادية في 30/09/2025. المنحة هي أسهم مقيدة مُصدرة وفقاً لــ Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan وتحتوي على تاريخ vesting وحيد هو 20 مايو 2028. الأسهم لديها سعر اكتساب مُبلغ عنه وهو $0 وهي قابلة للسحب إذا لم يتم إكمال فترة الخدمة المطلوبة. بعد المنح، يمتلك الشخص المبلغ عنه بشكل فاعل 150,000 سهماً مباشرة. النموذج موقع من الشخص المبلغ عنه في 02/10/2025.

PAVmed Inc. (PAVM) 报告了一份 Form 4,显示公司 总法律顾问 Michael A. Gordon 于 2025/09/30 获得了 150,000 股普通股。该奖励是根据发行人第六次经修订并再次修订的 2014 Long-Term Incentive Equity Plan 发行的受限股票,并具有单一的归属日期为 2028 年 5 月 20 日。这些股票的取得价格为 $0,如未完成所需的服务期限,将可能被没收。授予后,报告人直接受益拥有 150,000 股股票。该表格由报告人于 2025/10/02 签名。

Positive
  • None.
Negative
  • None.

PAVmed Inc. (PAVM) ha riportato un Form 4 che mostra che Michael A. Gordon, l'General Counsel dell'azienda, è stato assegnato 150.000 azioni ordinarie il 30/09/2025. Il premio è azioni soggette a restrizioni emesse ai sensi del Sesto Amended and Restated 2014 Long-Term Incentive Equity Plan dell'emittente e presenta una sola data di vesting del 20 maggio 2028. Le azioni hanno un prezzo di acquisizione riportato di $0 e sono soggette a perdita se non viene completato il periodo di servizio richiesto. Dopo l'assegnazione, la persona che riporta detiene beneficiamente 150.000 azioni direttamente. Il modulo è firmato dalla persona che riporta il 02/10/2025.

PAVmed Inc. (PAVM) reportó un Form 4 que muestra que Michael A. Gordon, el Asesor General de la empresa, recibió 150,000 acciones comunes el 30/09/2025. La adjudicación es de acciones restringidas emitidas conforme al Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan del emisor y tiene una única fecha de vesting el 20 de mayo de 2028. Las acciones tienen un precio de adquisición reportado de $0 y están sujetas a pérdidas si no se completa el periodo de servicio requerido. Después de la adjudicación, la persona que reporta posee beneficialmente 150,000 acciones directamente. El formulario está firmado por la persona que reporta el 02/10/2025.

PAVmed Inc. (PAVM)은 Michael A. Gordon이 회사의 General Counsel로서 150,000 주의 일반 주식을 2025년 9월 30일에 부여받았다고 Form 4를 통해 보고했습니다. 이 수여는 발행인의 제6차 수정 및 재정된 2014년 장기 인센티브 지분 계획에 따라 발행된 제한 주식이며, 단일 가취일은 2028년 5월 20일입니다. 주식의 취득가액은 $0이며 필요한 서비스 기간을 완료하지 못하면 몰수될 수 있습니다. 수여 이후 보고자는 직접적으로 150,000주를 수익적으로 소유합니다. 이 양식은 보고자가 2025년 10월 2일에 서명했습니다.

PAVmed Inc. (PAVM) a déclaré un formulaire 4 montrant que Michael A. Gordon, le conseiller juridique général de la société, a reçu 150 000 actions ordinaires le 30/09/2025. La récompense est des actions restreintes émises en vertu du Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan de l’émetteur et comporte une seule date d’acquisition, le 20 mai 2028. Les actions ont un prix d’acquisition déclaré de $0 et sont susceptibles d’être annulées si la période de service requise n’est pas accomplie. Après l’attribution, la personne déclarant détient avantageusement 150 000 actions directement. Le formulaire est signé par la personne déclarant le 02/10/2025.

PAVmed Inc. (PAVM) meldete ein Form 4, das zeigt, dass Michael A. Gordon, der General Counsel des Unternehmens, am 30.09.2025 150.000 Stammaktien erhalten hat. Die Zuwendung sind eingeschränkte Aktien, ausgegeben gemäß dem Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan des Emittenten, und sie hat ein einziges Vesting-Datum am 20. Mai 2028. Die Aktien haben einen gemeldeten Anschaffungspreis von $0 und unterliegen dem Verlust, falls der erforderliche Dienstzeitraum nicht abgeschlossen wird. Nach der Zuwendung besitzt die meldende Person direkt 150.000 Aktien beneficioell. Das Formular ist von der meldenden Person am 02.10.2025 unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Gordon Michael Adam

(Last) (First) (Middle)
360 MADISON AVENUE, 25TH FLOOR

(Street)
NEW YORK NY 10017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PAVmed Inc. [ PAVM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/30/2025 A 150,000(1) A $0(1) 150,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
/s/ Michael A. Gordon 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the PAVmed (PAVM) Form 4 report?

The Form 4 reports a grant of 150,000 restricted shares to Michael A. Gordon, the company's General Counsel, on 09/30/2025.

When do the restricted shares vest for the PAVmed (PAVM) grant?

The restricted shares have a single vesting date of May 20, 2028.

What is the acquisition price for the shares reported on the Form 4?

The filing reports an acquisition price of $0 for the 150,000 restricted shares.

How many shares does the reporting person own after the transaction?

Following the reported transaction, the reporting person beneficially owns 150,000 shares directly.

Are there conditions attached to the restricted shares?

Yes, the restricted stock is subject to forfeiture if the requisite service period is not completed.
Pavmed

NASDAQ:PAVM

PAVM Rankings

PAVM Latest News

PAVM Latest SEC Filings

PAVM Stock Data

9.55M
18.02M
18.43%
10.64%
1.15%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK